InsidersTradesSigma
Follow the Medartis Holding AG stock price and the full directors' dealings record of the company, a publicly traded company based in Switzerland. Shares trade on the CH market, under the supervision of SIX SER. Operating in the Healthcare & Pharma sector, Medartis Holding AG has published 77 insider filings. Market capitalisation: €1.1bn. The latest transaction was reported on 18 August 2026 (Sale). Every trade is free.
77
Insider Decl.
n/a
Thresholds
€13m
43 ops.
Buy Volume
€24m
34 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Medartis Holding AG Strong Buy (bullish), based on 3 analysts. Average price target: CHF 101.00.
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,143 of 29,053 companies
41.5
score / 100
Value31
Quality52
FCF yld0.8%
Earn yld0.8%
EV/EBITDA27.7x
ROE5.7%
Gross mgn76%
Net mgn3.1%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations77 total
1,344 shares@ CHF 92.020.011% mcap14.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8I00060
1,344 shares@ CHF 92.0176ISIN CH0386200239SIX:T1Q8I00060
372 shares@ CHF 67.150.0028% mcap3.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4T000D6
372 shares@ CHF 67.150.0028% mcap0.1% of flowISIN CH0386200239SIX:T1Q4T000D6
1,489 shares@ CHF 67.150.011% mcap14.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000K3
558 shares@ CHF 67.150.0042% mcap5.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000J5
1,489 shares@ CHF 67.150.011% mcap0.3% of flowISIN CH0386200239SIX:T1Q4R000K3
558 shares@ CHF 67.150.0042% mcap0.1% of flowISIN CH0386200239SIX:T1Q4R000J5
744 shares@ CHF 67.150.0056% mcap7.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000I0
7,445 shares@ CHF 67.150.056% mcap70.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000J8
7,445 shares@ CHF 67.150.056% mcap1.6% of flowISIN CH0386200239SIX:T1Q4O000J8
744 shares@ CHF 67.150.0056% mcap0.2% of flowISIN CH0386200239SIX:T1Q4O000I0
●
Anonymous (Executive member of the board of directors / member of senior management)
1,139 shares@ CHF 90.004.1% of flowISIN CH0386200239SIX:T1PCT00014
●
Anonymous (Executive member of the board of directors / member of senior management)
700 shares@ CHF 88.012.5% of flowISIN CH0386200239SIX:T1PCT00022
6,300 shares@ CHF 79.201.6% of flowISIN CH0386200239SIX:T1PCC000B8
18,939 shares@ CHF 79.204.8% of flowISIN CH0386200239SIX:T1PCC000D4
5,657 shares@ CHF 79.201.4% of flowISIN CH0386200239SIX:T1PCC000A0
8,333 shares@ CHF 79.202.1% of flowISIN CH0386200239SIX:T1PCC000P8
18,939 shares@ CHF 79.204.8% of flowISIN CH0386200239SIX:T1PCC000C6
6,313 shares@ CHF 79.201.6% of flowISIN CH0386200239SIX:T1PCC00085
17,576 shares@ CHF 79.204.5% of flowISIN CH0386200239SIX:T1PCC00093
126,276 shares@ CHF 79.2031.9% of flowISIN CH0386200239SIX:T1PCB000A1
715 shares@ CHF 88.00770.2% of flowISIN CH0386200239SIX:T1PC300058
1,441 shares@ CHF 85.16490.4% of flowISIN CH0386200239SIX:T1PBS00075
●
Anonymous (Executive member of the board of directors / member of senior management)
382 shares@ CHF 67.26651.0% of flowISIN CH0386200239SIX:T1PAR00079
25 of 77 declarations
About Medartis Holding AG
Medartis Holding AG is a Swiss medical device company listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. Founded in 1997 and headquartered in Basel, the company has built a focused franchise in orthopaedic surgical fixation, with particular strength in the craniomaxillofacial (CMF) segment and in solutions for upper and lower extremities. Its roots are tied to Switzerland’s precision manufacturing tradition, and its business model has been shaped around proprietary implant systems, surgeon-centric product design, and a strong clinical orientation. ([stockanalysis.com](https://stockanalysis.com/quote/swx/MED/company/?utm_source=openai)) Medartis develops, manufactures, and sells implant solutions used to stabilise and repair bone fractures. Its portfolio includes plates, screws, instruments, and related systems designed for trauma and reconstructive surgery. The company’s differentiation lies in the breadth of its orthopaedic offering, the technical quality of its products, and the usability of its systems in the operating room. From an investor perspective, Medartis combines a Swiss headquarters with an international commercial footprint, allowing it to pair “Swiss precision” with global reach across multiple healthcare markets. ([medartis.com](https://medartis.com/company/?utm_source=openai)) Competitive positioning is important. Medartis operates in a demanding segment of the medical technology market, where large global medtech groups compete for hospital access, surgeon preference, and product adoption. Within that landscape, Medartis stands out as a specialist rather than a broad-based orthopaedics conglomerate. This narrower focus can be an advantage: it supports technical depth, closer customer relationships, and a more targeted innovation pipeline. It also means the company’s market narrative is typically centred on share gains in niche indications, product launches, and geographic expansion rather than on scale alone. ([medartis.com](https://medartis.com/company/?utm_source=openai)) Recent developments have reinforced that growth profile. In March 2026, Medartis reported full-year 2025 sales of CHF 269.3 million and highlighted improved operating profitability, while also describing an organisational shift toward a more decentralised, multi-brand structure. In April 2026, shareholders strongly approved the board’s proposals at the AGM. The market had also paid attention to management and board-related transactions disclosed through the Swiss disclosure framework in late 2025, which is relevant for investors following SIX-regulated reporting and governance signals. Overall, Medartis presents as a niche Swiss medtech name with international ambitions, supported by operating momentum and a disciplined strategic focus. ([eqs-news.com](https://www.eqs-news.com/news/ad-hoc/medartis-builds-on-momentum-with-16-organic-sales-growth-and-core-ebitda-margin-exceeding-18/2065ea62-13b4-40e4-a62c-acc32c2b9cd3?utm_source=openai))
